+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tropical & Vector-borne Infectious Diseases Market - Global Forecast 2026-2032- Product Image
Tropical & Vector-borne Infectious Diseases Market - Global Forecast 2026-2032- Product Image
Sale

Tropical & Vector-borne Infectious Diseases Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6082177
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tropical & Vector-borne Infectious Diseases Market is projected to reach USD 6.77 Billion in 2026. It is expected to continue growing at a CAGR of 9.90%, reaching USD 11.91 Billion by 2032.

Tropical and Vector-Borne Diseases: Executive Overview

Tropical and vector-borne infectious diseases remain shaped by interactions among pathogens, hosts, vectors, climate, land use, mobility, health-system capacity, and socioeconomic conditions. The burden is concentrated unevenly, with dengue, malaria, chikungunya, yellow fever, leishmaniasis, lymphatic filariasis, schistosomiasis, and other infections requiring distinct surveillance, prevention, diagnosis, treatment, and vaccination approaches. Effective responses increasingly combine public-health infrastructure with environmental management, community engagement, laboratory capacity, and rapid access to care.

Climate, Mobility, and Urbanization Are Reshaping Disease Control

Changing temperature and rainfall patterns can alter vector survival, breeding conditions, pathogen development, and seasonal transmission windows. Urban growth, informal settlements, deforestation, agricultural expansion, and water-storage practices can create or intensify exposure pathways. International travel, migration, trade, and displacement also increase the need for coordinated surveillance and preparedness across borders. These shifts make locally tailored, continuously updated interventions more important than uniform approaches.

Artificial Intelligence Strengthens Surveillance, Diagnosis, and Response

Artificial intelligence can support early-warning systems by combining case reports, laboratory results, weather observations, vector data, mobility indicators, and geospatial information. Image-analysis tools may assist laboratory and point-of-care workflows, while predictive models can help prioritize testing, vector-control operations, vaccine deployment, and clinical resources. Benefits depend on representative data, external validation, interoperability, cybersecurity, transparent governance, and human oversight; biased or incomplete datasets can otherwise reinforce blind spots and produce unreliable alerts.

Regional Priorities Differ Across Six Major Geographies

In North America, preparedness emphasizes imported infections, local transmission risk, travel medicine, laboratory readiness, and vector expansion. Latin America faces recurrent arboviral outbreaks alongside persistent malaria, Chagas disease, leishmaniasis, and yellow-fever concerns, requiring integrated vector control and equitable access. Europe focuses on imported cases, expanding suitability for selected vectors, and coordinated surveillance. The Middle East must address climate-sensitive transmission, population movement, water and sanitation conditions, and fragile health systems. Africa carries a substantial malaria burden and also confronts arboviruses, neglected tropical diseases, conflict-related disruption, and diagnostic-access gaps. Asia-Pacific combines dense urban transmission, monsoon variability, island and remote-area access challenges, and cross-border disease movement.

Multilateral Groups Need Complementary, Not Identical, Strategies

ASEAN cooperation is especially relevant for cross-border surveillance, shared vector-control practices, and travel-related transmission across highly connected settings. BRICS members can strengthen collaboration on diagnostics, research, manufacturing capacity, and health-system resilience while accounting for diverse epidemiological profiles. The European Union benefits from interoperable surveillance, coordinated preparedness, and shared technical guidance. G7 members can support financing, research partnerships, and global preparedness. GCC countries require strong importation surveillance, migrant-health services, and climate-sensitive vector monitoring. NATO members should incorporate infectious-disease readiness, medical logistics, and resilience of critical health infrastructure into broader security planning.

Country Priorities Reflect Distinct Epidemiological and System Contexts

Australia emphasizes surveillance of dengue and other imported or emerging threats, including risks associated with travel and vector range changes. Brazil requires sustained action on dengue, malaria, yellow fever, Chagas disease, and other endemic infections. Canada prioritizes imported disease preparedness and monitoring of locally suitable vectors. China combines large-scale surveillance, urban outbreak control, and prevention of imported and regionally circulating infections. France, Germany, Italy, Spain, and the United Kingdom focus on travel-associated disease, laboratory readiness, and changing vector suitability. India faces substantial dengue, malaria, chikungunya, Japanese encephalitis, and neglected tropical disease needs across varied states and climates. Japan and South Korea emphasize surveillance, travel medicine, and preparedness for imported or re-emerging infections. Mexico requires integrated management of dengue, malaria, Chagas disease, and other regional threats. Russia must address diverse climatic zones, imported infections, and vector surveillance. The United States combines domestic vector monitoring with travel-related preparedness, diagnostic capacity, and outbreak response.

Leadership Priorities for More Resilient Disease Control

Industry and health leaders should prioritize interoperable surveillance that links clinical, laboratory, entomological, environmental, and mobility data while protecting privacy. They should validate diagnostic and AI-enabled tools in the populations and settings where they will be used, strengthen last-mile distribution and cold-chain reliability, and design interventions with local communities. Portfolio planning should combine vaccines where available with vector control, habitat management, protective behaviors, rapid diagnosis, effective treatment, and workforce training. Leaders should also establish measurable response triggers, conduct scenario exercises for climate and mobility disruptions, and build partnerships that preserve access in rural, remote, displaced, and underserved populations.

Evidence-Based Methodology for the Executive Summary

This summary uses the defined market scope of tropical and vector-borne infectious diseases and synthesizes established public-health relationships among pathogens, vectors, hosts, environments, and health systems. Insights are organized across the required regions, multilateral groups, and countries, with emphasis on documented disease-control mechanisms, surveillance needs, climate sensitivity, mobility, and operational capacity. No market estimates, market sizing, market shares, forecasts, or company-specific claims are used. Interpretations should be validated against current national surveillance, guidance from competent health authorities, peer-reviewed research, and disease-specific evidence before operational decisions are made.

Integrated Preparedness Is the Most Durable Strategic Response

The disease landscape is becoming more interconnected through climate variability, urbanization, mobility, ecological change, and uneven health-system capacity. Durable progress depends on combining prevention, surveillance, diagnostics, treatment, vaccination where appropriate, vector management, and community participation rather than relying on a single technology or intervention. Organizations that invest in trusted data systems, locally appropriate delivery models, responsible artificial intelligence, and cross-border coordination will be better positioned to detect transmission early and protect populations as risks evolve.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tropical & Vector-borne Infectious Diseases Market, by Disease Type
7.1. Introduction
7.2. Chagas Disease
7.3. Dengue
7.4. Leishmaniasis
7.5. Malaria
7.6. West Nile Virus
7.7. Zika Virus
8. Tropical & Vector-borne Infectious Diseases Market, by Therapeutic Application
8.1. Introduction
8.2. Immunoglobulins
8.3. Therapeutics
8.3.1. Antibiotics
8.3.2. Antimalarials
8.3.3. Antivirals
8.4. Vaccines
8.4.1. Live Attenuated
8.4.2. mRNA
8.4.3. Recombinant
9. Tropical & Vector-borne Infectious Diseases Market, by Diagnostic Method
9.1. Introduction
9.2. Microscopy
9.3. Molecular Diagnostics
9.3.1. LAMP
9.3.2. PCR
9.4. Rapid Diagnostic Tests
9.4.1. Chikungunya RDT
9.4.2. Dengue RDT
9.4.3. Malaria RDT
9.5. Serological Tests
10. Tropical & Vector-borne Infectious Diseases Market, by End User
10.1. Introduction
10.2. Diagnostic Centers
10.3. Hospitals & Clinics
10.4. Research Institutes
11. Tropical & Vector-borne Infectious Diseases Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Tropical & Vector-borne Infectious Diseases Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Tropical & Vector-borne Infectious Diseases Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. Abbott Laboratories
15.2. Bayer AG
15.3. Bharat Biotech International Limited
15.4. Bio-Rad Laboratories, Inc.
15.5. BioNTech SE
15.6. Chembio Diagnostics, Inc.
15.7. Eisai Co., Ltd.
15.8. Gilead Sciences, Inc.
15.9. GlaxoSmithKline plc
15.10. InBios International, Inc.
15.11. Johnson & Johnson
15.12. Merck & Co., Inc.
15.13. Meridian Bioscience, Inc.
15.14. Novartis AG
15.15. Novavax, Inc.
15.16. Pfizer Inc.
15.17. Roche Diagnostics
15.18. Sanofi S.A.
15.19. Serum Institute of India Pvt. Ltd.
15.20. Takeda Pharmaceutical Company Limited
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Tropical & Vector-borne Infectious Diseases Market, Years Considered for the Study
FIGURE 2. Global Tropical & Vector-borne Infectious Diseases Market, Research Design
FIGURE 3. Global Tropical & Vector-borne Infectious Diseases Market, Research Framework
FIGURE 4. Global Tropical & Vector-borne Infectious Diseases Market, Data Triangulation
FIGURE 5. Global Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2025 vs 2032 (%)
FIGURE 7. Global Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2025 vs 2032 (%)
FIGURE 9. Global Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2025 vs 2032 (%)
FIGURE 11. Global Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Tropical & Vector-borne Infectious Diseases Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Tropical & Vector-borne Infectious Diseases Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Tropical & Vector-borne Infectious Diseases Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Tropical & Vector-borne Infectious Diseases Market Segmentation & Coverage
TABLE 2. Global Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 3. Global Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 4. Global Chagas Disease Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Chagas Disease Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Chagas Disease Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Dengue Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Dengue Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Dengue Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Leishmaniasis Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Leishmaniasis Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Leishmaniasis Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Malaria Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Malaria Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Malaria Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global West Nile Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global West Nile Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global West Nile Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Zika Virus Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Zika Virus Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Zika Virus Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 23. Global Immunoglobulins Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Immunoglobulins Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Immunoglobulins Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Antibiotics Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Antibiotics Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Antibiotics Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Antimalarials Market Size, by Region, 2017-2032 (USD Million)
TABLE 33. Global Antimalarials Market Size, by Group, 2017-2032 (USD Million)
TABLE 34. Global Antimalarials Market Size, by Country, 2017-2032 (USD Million)
TABLE 35. Global Antivirals Market Size, by Region, 2017-2032 (USD Million)
TABLE 36. Global Antivirals Market Size, by Group, 2017-2032 (USD Million)
TABLE 37. Global Antivirals Market Size, by Country, 2017-2032 (USD Million)
TABLE 38. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 39. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 40. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 41. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 42. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 43. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 44. Global mRNA Market Size, by Region, 2017-2032 (USD Million)
TABLE 45. Global mRNA Market Size, by Group, 2017-2032 (USD Million)
TABLE 46. Global mRNA Market Size, by Country, 2017-2032 (USD Million)
TABLE 47. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 48. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 49. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 50. Global Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 51. Global Microscopy Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Microscopy Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Microscopy Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Molecular Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Molecular Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Molecular Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global LAMP Market Size, by Region, 2017-2032 (USD Million)
TABLE 58. Global LAMP Market Size, by Group, 2017-2032 (USD Million)
TABLE 59. Global LAMP Market Size, by Country, 2017-2032 (USD Million)
TABLE 60. Global PCR Market Size, by Region, 2017-2032 (USD Million)
TABLE 61. Global PCR Market Size, by Group, 2017-2032 (USD Million)
TABLE 62. Global PCR Market Size, by Country, 2017-2032 (USD Million)
TABLE 63. Global Rapid Diagnostic Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Rapid Diagnostic Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Rapid Diagnostic Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Chikungunya RDT Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Chikungunya RDT Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Chikungunya RDT Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Dengue RDT Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Dengue RDT Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Dengue RDT Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Malaria RDT Market Size, by Region, 2017-2032 (USD Million)
TABLE 73. Global Malaria RDT Market Size, by Group, 2017-2032 (USD Million)
TABLE 74. Global Malaria RDT Market Size, by Country, 2017-2032 (USD Million)
TABLE 75. Global Serological Tests Market Size, by Region, 2017-2032 (USD Million)
TABLE 76. Global Serological Tests Market Size, by Group, 2017-2032 (USD Million)
TABLE 77. Global Serological Tests Market Size, by Country, 2017-2032 (USD Million)
TABLE 78. Global Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 79. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Hospitals & Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Global Hospitals & Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 84. Global Hospitals & Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 85. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 86. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 87. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 88. Global Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 98. North America Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 99. North America Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 100. North America Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 101. North America Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 102. North America Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 103. North America Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 104. North America Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 105. North America Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 106. North America Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 107. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 109. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 110. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 111. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 112. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 113. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 114. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 115. Latin America Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 116. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 118. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 119. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 120. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 121. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 122. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 123. Europe Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 124. Europe Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 125. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 127. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 128. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 129. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 130. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 131. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 132. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 133. Middle East Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 134. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
TABLE 135. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 136. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 137. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 138. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 139. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 140. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 141. Africa Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 142. Africa Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 143. Global Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 146. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 147. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 148. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 149. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 150. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 151. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 152. ASEAN Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 153. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 154. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 155. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 156. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 157. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 158. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 159. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 160. GCC Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 161. GCC Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 162. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 163. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 164. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 165. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 166. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 167. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 168. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 169. European Union Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 170. European Union Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 173. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 174. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 175. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 176. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 177. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 178. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 179. BRICS Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 180. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 181. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 182. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 183. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 184. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 185. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 186. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 187. G7 Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 188. G7 Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 189. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 191. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 192. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 193. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 194. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 195. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 196. NATO Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 197. NATO Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 198. Global Tropical & Vector-borne Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
TABLE 199. United States Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 200. United States Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 201. United States Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 202. United States Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 203. United States Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 204. United States Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 205. United States Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 206. United States Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 207. United States Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 208. Canada Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 209. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 210. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 211. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 212. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 213. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 214. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 215. Canada Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 216. Canada Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 217. Mexico Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 218. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 219. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 220. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 221. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 222. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 223. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 224. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 225. Mexico Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 226. Brazil Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 227. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 228. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 229. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 230. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 231. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 232. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 233. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 234. Brazil Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 235. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 236. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 237. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 238. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 239. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 240. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 241. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 242. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 243. United Kingdom Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. Germany Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 245. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 246. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 247. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 248. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 249. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 250. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 251. Germany Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 252. Germany Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 253. France Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 254. France Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 255. France Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 256. France Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 257. France Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 258. France Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 259. France Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 260. France Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 261. France Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. Russia Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 263. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 264. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 265. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 266. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 267. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 268. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 269. Russia Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 270. Russia Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 271. Italy Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 272. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 273. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 274. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 275. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 276. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 277. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 278. Italy Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 279. Italy Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 280. Spain Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 281. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 282. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 283. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 284. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 285. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 286. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 287. Spain Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 288. Spain Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 289. China Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 290. China Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 291. China Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 292. China Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 293. China Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 294. China Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 295. China Tropical & Vector-borne Infectious Diseases Market Size, by Molecular Diagnostics, 2017-2032 (USD Million)
TABLE 296. China Tropical & Vector-borne Infectious Diseases Market Size, by Rapid Diagnostic Tests, 2017-2032 (USD Million)
TABLE 297. China Tropical & Vector-borne Infectious Diseases Market Size, by End User, 2017-2032 (USD Million)
TABLE 298. India Tropical & Vector-borne Infectious Diseases Market Size, 2017-2032 (USD Million)
TABLE 299. India Tropical & Vector-borne Infectious Diseases Market Size, by Disease Type, 2017-2032 (USD Million)
TABLE 300. India Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutic Application, 2017-2032 (USD Million)
TABLE 301. India Tropical & Vector-borne Infectious Diseases Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 302. India Tropical & Vector-borne Infectious Diseases Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 303. India Tropical & Vector-borne Infectious Diseases Market Size, by Diagnostic Method, 2017-2032 (USD Million)
TABLE 304. India Tropical & Vector-borne Infectious Diseases Market Size, by Mole

Companies Mentioned

  • Abbott Laboratories
  • Bayer AG
  • Bharat Biotech International Limited
  • Bio-Rad Laboratories, Inc.
  • BioNTech SE
  • Chembio Diagnostics, Inc.
  • Eisai Co., Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • InBios International, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Meridian Bioscience, Inc.
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Roche Diagnostics
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Takeda Pharmaceutical Company Limited

Related Topics

Related Reports

Zika Virus Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (, Molecular Tests (RT-PCR, NAAT), Serologic Tests (IgM/IgG ELISA), Plaque-Reduction Neutralisation Test (PRNT)), Sample Type, End-User - Product Image

Zika Virus Testing Market Outlook 2026-2034: Market Share, and Growth Analysis by Test Type (, Molecular Tests (RT-PCR, NAAT), Serologic Tests (IgM/IgG ELISA), Plaque-Reduction Neutralisation Test (PRNT)), Sample Type, End-User

  • Report
  • 160 Pages
  • Global
From
Arthropod-borne Viral Infections Testing Market - Global Forecast 2026-2032 - Product Image

Arthropod-borne Viral Infections Testing Market - Global Forecast 2026-2032

  • Report
  • 187 Pages
  • Global
From
Neglected Tropical Diseases Diagnosis Market - Global Forecast 2026-2032 - Product Image

Neglected Tropical Diseases Diagnosis Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Diagnostic Reagents for Infectious Diseases Market Size, Share & Trends Analysis Report by Product (Molecular Reagents, Immunoassay Reagents), Disease Area (Respiratory Infections, Enteric Infections), Technology, End Use and Region with Growth Forecasts, 2025-2033 - Product Image

Diagnostic Reagents for Infectious Diseases Market Size, Share & Trends Analysis Report by Product (Molecular Reagents, Immunoassay Reagents), Disease Area (Respiratory Infections, Enteric Infections), Technology, End Use and Region with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Infectious Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Infectious Disease Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.